Literature DB >> 24171478

Structure-activity relationship study of permethyl ningalin B analogues as P-glycoprotein chemosensitizers.

Jin Wen Bin1, Iris L K Wong, Xuesen Hu, Zhang Xiao Yu, Li Fu Xing, Tao Jiang, Larry M C Chow, Wan Sheng Biao.   

Abstract

A novel series of permethyl ningalin B analogues were synthesized and evaluated for their P-glycoprotein (P-gp)-modulating activities in a P-gp-overexpressing breast cancer cell line (LCC6MDR). Compounds 35 and 37, which possess one methoxy group and one benzyloxy group at aryl ring C, displayed the most potent P-gp-modulating activity. A 1 μM concentration of 35 and 37 resensitized LCC6MDR cells toward paclitaxel by 42.7-fold, with respective EC50 values of 93.5 and 110.0 nM. Their mechanism of P-gp modulation is associated with an increase in intracellular drug accumulation. Their advantages also include low cytotoxicity (IC50 for L929 fibroblast >100 μM) and high therapeutic indexes (>909 after normalization with their EC50 values). 35 is not a substrate of P-gp. They are potentially dual-selective modulators for both P-gp and breast cancer resistance protein transporters. The present study demonstrates that these new compounds can be employed as effective and safe modulators of P-gp-mediated drug resistance in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24171478     DOI: 10.1021/jm400930e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Modification of marine natural product ningalin B and SAR study lead to potent P-glycoprotein inhibitors.

Authors:  Chao Yang; Iris L K Wong; Wen Bin Jin; Tao Jiang; Larry M C Chow; Sheng Biao Wan
Journal:  Mar Drugs       Date:  2014-10-17       Impact factor: 5.118

Review 2.  The Effects of Synthetically Modified Natural Compounds on ABC Transporters.

Authors:  Daniel Dantzic; Pawan Noel; Fabrice Merien; Dong-Xu Liu; Jun Lu; Haiyong Han; Mark J McKeage; Yan Li
Journal:  Pharmaceutics       Date:  2018-08-09       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.